Fluticasone propionate as a potential treatment for COVID-19. Academic Article uri icon

Overview

abstract

  • Outpatient treatment options for mild to moderate COVID-19 are severely limited. While many therapeutic options have been proposed, very few have demonstrated the appropriate safety and efficacy to warrant approval by national or international regulatory bodies. Monoclonal antibodies have been shown to decrease hospitalization in high-risk patients, but use remains limited due to challenges associated with both production and administration, and other treatment options are urgently needed. The anti-inflammatory drug fluticasone propionate has recently emerged as a potential outpatient treatment option, especially for those with newly diagnosed disease. This manuscript reviews what is known about fluticasone and looks ahead to examine how the drug may be used in the future to address the COVID-19 pandemic.

publication date

  • May 1, 2022

Research

keywords

  • Anti-Asthmatic Agents
  • Asthma
  • COVID-19
  • COVID-19 Drug Treatment

Identity

Scopus Document Identifier

  • 85129569926

Digital Object Identifier (DOI)

  • 10.1358/dot.2022.58.5.3381591

PubMed ID

  • 35535815

Additional Document Info

volume

  • 58

issue

  • 5